Medasense Biometrics

Company Overview

Snapshot

Founded in June 2008 by Galit Zuckerman, Medasense Biometrics operates with 11–50 employees. The company has raised $33.5 million across 5 funding rounds from 9 investors. In January 2025, the company secured funding from the BIRD Foundation.

Business overview

Medasense Biometrics develops technology that enables clinicians to optimize and personalize pain control, aiming to prevent overmedication. Its core product, the PMD-200 with the NOL index, is an AI-powered platform utilizing a proprietary noninvasive sensor to objectively monitor and quantify a patient's pain response. This technology is designed for pain management in operating rooms and critical care settings, particularly for patients unable to communicate. The PMD-200 is distributed in Europe by Medtronic and is cleared for marketing in Canada, Latin America, Israel, and Australia, offering connectivity with Philips patient monitors. The company operates within the Health Tech & Life Sciences sector, focusing on digital healthcare, medical devices, and patient remote monitoring.

Strategic signal

In February 2023, the FDA authorized the marketing of Medasense's NOL technology for measuring pain in anesthetized patients. This regulatory approval is a significant validation of the company's non-invasive pain monitoring solution, expanding its market access within the critical care and surgical environments in the United States. It signals strong potential for broader adoption and impact on patient safety and outcomes by providing objective pain assessment where verbal communication is not possible.

Company Intelligence Q&A

What is Medasense Biometrics' primary offering?

Medasense Biometrics offers the PMD-200, a platform featuring its proprietary NOL index. This system uses artificial intelligence and noninvasive sensors to objectively monitor and quantify a patient's pain response, optimizing pain management in settings where patients cannot communicate.

Which investors participated in Medasense Biometrics' September 2020 funding round?

In September 2020, Medasense Biometrics received funding from Sabadell Asabys VC and OTV.

What significant regulatory milestone did Medasense Biometrics achieve in 2023?

In February 2023, the FDA authorized the marketing of Medasense Biometrics' NOL technology, allowing it to be used for measuring pain in anesthetized patients.

Which investors participated in Medasense Biometrics' November 2015 funding round?

In November 2015, Medasense Biometrics received funding from lead investor OTV.